Monday, December 17, 2007
Industry-Supported Studies Comparing Viagra and Cialis.
Until well-designed, randomized, placebo-controlled clinical trials are conducted, it will not be possibility to make any definitive comparisons of the 3 PDE-5 inhibitors. In the motion reappraisal of studies presented at the ISSIR assembly, shortcomings in affliction sketch are noted that might make the results less than conclusive.
There were 3 industry-sponsored, multicenter clinical trials with open-label, 1-way, borrowing aim. In these studies, patients documented several weeks of viagra use either prospectively or retrospectively and then were crossed over for several weeks of open-label use of cheap tadalafil. Data on tadalafil were recorded prospectively with measure questionnaires (International Fact of Erectile Mapping [IIEF], Global Cost Question) as well as with a newly developed psychometric questionnaire (the Psychological and Interpersonal State Scales [PAIRS]). Four fencesitter trials sponsored by large clinics or universities were presented; in these trials, all 3 tablets were made available to patients sequentially for at least 1 calendar month or 3-4 doses. Validated as well as unvalidated questionnaires were used for data accrual.
This is a part of article Industry-Supported Studies Comparing Viagra and Cialis. Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
